Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 15, 2015

Primary Completion Date

November 15, 2018

Study Completion Date

December 15, 2021

Conditions
Ovarian Cancer
Interventions
DRUG

Niraparib

Niraparib versus Bevacizumab-Niraparib combo

DRUG

Bevacizumab

Trial Locations (2)

2100

Rigshospitalet, Copenhagen

Unknown

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

collaborator

Gynecologic Cancer Intergroup (GCIG)

OTHER

collaborator

University of Utah

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Myriad Genetics, Inc.

INDUSTRY

lead

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

OTHER